Drugs Information:
Ibalizumab
Basic Information
|
||
| ID | DDInter2255 | |
| Drug Type | biotech | |
| Protein Chemical Formula | None | |
| Protein Average Weight | - | |
| CAS Number | 680188-33-4 | |
| Description | Ibalizumab (also known as _ibalizumab-uiyk_ and formerly known as TNX-355) is a monoclonal antibody that binds to CD4 receptors on the surface of CD4-positive cells, preventing HIV particle entry into the lymphocytes. It is an advanced and current antibody in development for the treatment of HIV/AIDS. It has been developed by Taimed biologics and Theratechnologies [L1558, L1554]. This drug was approved in March 2018 for the management of treatment-resistant HIV [L1554]. In October 2022, the FDA approved the administration of Trogarzo (ibalizumab-uiyk) by intravenous push, allowing for a faster drug administration.[L43443,L43448] | |
| ATC Classification | J05AX23 | |
| Sequences | None | |
| Useful Links | DrugBank PubChem Substance Wikipedia | |
Interactions with
Ibalizumab
Filter:
| Severity level | ID | Name | Mechanism | Detail |
|---|
Interactions with diseases
Filter:
| Severity level | Disease name | Text | References |
|---|
Interactions with foods
Filter:
| Severity level | Food name | Description | Management | Mechanism | References |
|---|
Interactions with compound preparation
| Multi-DRUG trade | Multi-DRUG | Drug type | Warning | Note |
|---|